Pfizer Licenses AnTolRx Type 1 Diabetes Candidate

Pfizer exercises option granted in 2016 to exclusively license lead immunotherapeutic.

Biotech company AnTolRx is developing targeted antigen-specific therapies based on immune tolerance induction rather than immune suppression for several inflammatory and autoimmune diseases. With its approach, an immunomodulatory aryl hydrocarbon receptor agonist is co-delivered with specific antigens to generate disease-specific Treg cells to treat immunological disorders.

Pfizer has elected to exercise an option it was granted in a June 2016 agreement to license the AnTolRx's lead candidate in type 1 diabetes.

Pfizer will pay AnTolRx an up-front payment (and potential milestone and royalty fees) in exchange for exclusive rights to pursue further optimization, development and potential commercialization of the antigen-specific immunotherapy.



Cynthia A. Challener, Ph.D.

Dr. Challener is an established industry editor and technical writing expert in the areas of chemistry and pharmaceuticals. She writes for various corporations and associations, as well as marketing agencies and research organizations, including That’s Nice and Nice Insight.